

Remarks

Claim 20 is pending and has been amended. The subject matter defining the compounds of formula I of claim 16 has been incorporated into claim 20. Claims 16, 17, 18, 19, 21-28 have been cancelled.

Election/Restriction


Applicants wish to provisionally elect without traverse Group III, which is claim 20, drawn to a method for enhancing graft survival following transplant. Applicants reserve the right to file divisional applications pertaining to the subject matter in Groups I, II and IV.

The election of species is N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide.

Entry of this Response is respectfully requested.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852


Oona A. Manzari
Attorney for Applicant
Reg. No. 48,152

Date: 1/3/08